ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2020 Earnings Conference Call March 9, 2021 8:30 AM ET Company Participants Lisa Wilson - In-Site Communications, Investor Relations Nikhil Lalwani - President & Chief Executive Officer Stephen Carey - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Elliot Wilbur - Raymond James Dana Flanders - Guggenheim Operator Good morning, and welcome to today's program. My name is Maria, and I'll be your conference operator. At this tim ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2020 Results Earnings Conference Call November 5, 2020 10:30 AM ET Company Participants Lisa Wilson - In-Site Communications, IR Nikhil Lalwani - President and CEO Stephen Carey - Chief Financial Officer Conference Call Participants Dana Flanders - Guggenheim Elliot Wilbur - Raymond James Brandon Folkes - Cantor Fitzgerald Operator Good morning. And welcome to today’s program. My name is Nicole, and I will be your conference operator. At this time, I would like to ...

Table of Contents Titleofeachclass:Trading CommonStock UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its char ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2020 Results Conference Call August 6, 2020 10:30 AM ET Company Participants Lisa Wilson - In-Site Communications, IR Patrick Walsh - Interim President and CEO Stephen Carey - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Dana Flanders - Guggenheim Operator Good morning, everyone, and welcome to ANI's Second Quarter 2020 Earnings Conference Call. [Operator Instructions] Please note this call may be recorded. It is now my pleasure to turn today ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other j ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2020 Earnings Conference Call May 7, 2020 10:30 AM ET Company Participants Arthur Przybyl - Chief Executive Officer Stephen Carey - Chief Financial Officer Patrick Walsh - ANI Board Member Conference Call Participants Operator Good morning, everyone, and welcome to ANI's First Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. It is now my pleasure to turn today's program over to Mr. Arthur Przybyl, President and CEO of ANI Pharm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other jurisdiction of in ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2019 Earnings Conference Call February 27, 2020 10:30 AM ET Company Participants Arthur Przybyl - CEO Stephen Carey - CFO Conference Call Participants Dana Flanders - Guggenheim Elliot Wilbur - Raymond James Brandon Folkes - Cantor Fitzgerald Operator Good morning, everyone, and welcome to ANI's Fourth Quarter 2019 Earnings Call. [Operator Instructions]. Please note, this call may be recorded. It is now my pleasure to turn today's program over to Mr. Arthur Przybyl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other jurisdic ...